What is the current market size?

The Diagnostic Testing of STDs market size was valued at approximately USD 1.2 billion in 2023, driven by increased awareness and healthcare investments.

What is the expected growth rate?

The future outlook projects a CAGR of 5.5% from 2026 to 2033, fueled by technological advancements and rising incidence of sexually transmitted infections.

What are the key drivers of this market?

Key drivers include growing public health campaigns, demand for rapid diagnostic tools, and the rise in sexually transmitted disease prevalence globally.

What challenges does the market face?

Challenges include high testing costs, limited access in low-income regions, and social stigma associated with STD diagnoses and testing.

Which regions are leading the market?

North America and Europe lead due to robust healthcare infrastructure, while Asia-Pacific shows high growth potential from expanding diagnostics networks.

Who are the top companies in this sector?

Leading companies include Roche Diagnostics, Abbott Laboratories, BD (Becton, Dickinson), and Thermo Fisher Scientific, dominating with innovative test kits.

What future opportunities exist?

Opportunities lie in point-of-care testing adoption, telemedicine integration, and expansion into underserved markets with portable diagnostic devices.

How is technology shaping the market?

Advancements like PCR-based tests, multiplex assays, and AI-driven diagnostics are enhancing accuracy, speed, and scalability of STD testing solutions.

What about the regulatory landscape?

Regulatory bodies like FDA and EMA play a critical role in approving rapid tests, ensuring compliance, and promoting standardized diagnostic protocols.

Diagnostic Testing of STDs Value Chain Analysis & Forecast Outlook 2033

Diagnostic Testing of STDs by Application (Hospitals, Clinics), by Types (Chlamydia testing, Gonorrhea testing, P&S Syphilis testing, HPV testing, HSV testing, HIV testing, Chancroid testing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Diagnostic Testing of STDs Market Size | CAGR 2019 Forecast 2033

Diagnostic Testing of STDs Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 96

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 96

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Diagnostic Testing of STDs Market Overview

The Diagnostic Testing of STDs market encompasses solutions for identifying sexually transmitted infections such as HIV, chlamydia, syphilis, and gonorrhea. With rising global health concerns and regulatory emphasis on disease prevention, this sector holds critical relevance in public health infrastructure. The Diagnostic Testing of STDs market size is projected to grow significantly, driven by advancements in testing technologies, expanded healthcare access, and heightened awareness of infectious diseases. This market forecast underscores an industry expansion trajectory shaped by macroeconomic and technological shifts.

Loading chart…

The Diagnostic Testing of STDs market is valued at approximately $4.1 billion in 2025 and is anticipated to grow at a CAGR of 6.5% from 2026 to 2033. Key drivers include innovations in point-of-care diagnostics, which reduce testing time and improve accessibility, and stringent regulatory frameworks promoting routine screening in high-risk demographics. North America dominates the market, accounting for 38% of global revenue, while Southeast Asia emerges as the fastest-growing region due to rising healthcare investments and digital health adoption. Strategic collaborations between diagnostic firms and public health agencies further accelerate market penetration.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Abbott; Becton Dickinson; BioMerieux; Danaher; Hologic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of sexually transmitted diseases (STDs): The increasing incidence of infections such as chlamydia, gonorrhea, and HIV is fueling demand for diagnostic testing of STDs market. Public health initiatives emphasizing early detection and treatment further accelerate market growth.

Technological advancements in rapid diagnostics: Innovations like point-of-care (POC) testing and molecular assays are enhancing accuracy and reducing turnaround time, driving adoption in both clinical and home testing settings.

Restraints2 items

High costs of advanced diagnostic technologies: Premium pricing of next-gen tests, such as nucleic acid amplification tests (NAATs), limits accessibility in low- and middle-income regions, constraining diagnostic testing of STDs market size expansion.

Regulatory delays in approval processes: Stringent regulatory requirements for test validation and quality control in regions like Europe and North America create bottlenecks, slowing market entry for novel diagnostic tools.

Opportunities2 items

Rising adoption of home-based testing kits: Growing consumer preference for privacy and convenience is unlocking new revenue streams, particularly in mature markets with established e-commerce healthcare ecosystems.

Expansion into underserved rural regions: Government partnerships and mobile health clinics in emerging markets offer untapped potential to scale diagnostic testing of STDs market reach, supported by telemedicine integration.

Challenges2 items

Stigma and underreporting of STDs: Cultural taboos surrounding sexual health deter individuals from seeking testing, leading to incomplete data and misaligned growth forecast models for diagnostic providers.

Supply chain disruptions for critical reagents: Global shortages of PCR testing components and logistical bottlenecks during pandemics threaten consistent product availability, impacting market reliability.

Market Segmentation

Loading chart…

Application Segmentation: The Diagnostic Testing of STDs market is categorized by application into clinical diagnostics, public health programs, and research. Clinical diagnostics dominate, accounting for ~50% of the market, driven by hospital and clinic demand for rapid, accurate results to guide treatment. Public health programs constitute ~30%, reflecting government and NGO initiatives for screening and disease surveillance. Research applications contribute ~20%, fueled by academic institutions and biotech firms exploring novel diagnostic technologies. These segments collectively shape the Diagnostic Testing of STDs segmentation, with clinical adoption and regulatory frameworks influencing growth trajectories.

Types Segmentation: By types, the market includes molecular tests (e.g., PCR), serological assays (e.g., ELISA), and rapid antigen tests. Molecular tests lead at ~40% due to their high specificity and multiplexing capabilities for detecting HIV, chlamydia, and gonorrhea. Serological tests capture ~35% of the market, favored for affordability and ease of use in resource-limited settings. Rapid antigen tests account for ~25%, growing in popularity for point-of-care settings requiring immediate results. This market taxonomy underscores technological diversification, with innovation in molecular diagnostics and cost-effectiveness in serological methods driving competitive dynamics.

Diagnostic Testing of STDs Segmentation Breakdown11 items

Application

Hospitals

Clinics

Types

Chlamydia testing

Gonorrhea testing

P&S Syphilis testing

HPV testing

HSV testing

HIV testing

Chancroid testing

Regional Insights

Loading chart…

The Diagnostic Testing of STDs market is dominated by North America, which accounts for ~35% of global revenue, driven by advanced healthcare infrastructure, high prevalence of sexually transmitted infections, and robust investment in diagnostic innovation. The region's mature ecosystem is supported by proactive public health policies and widespread adoption of rapid testing technologies. The fastest-growing region is Asia Pacific, projected to expand at a CAGR of 12% through 2030, fueled by rising awareness, expanding healthcare access in emerging economies, and government initiatives to combat infectious diseases.

Europe holds ~30% of the market, reflecting strong regulatory frameworks, high testing rates, and integration of point-of-care diagnostics in primary care settings. However, fragmented healthcare systems across smaller EU nations present growth challenges. Latin America (10% share) and the Middle East & Africa (5% share) are gaining traction through public-private partnerships and NGO-driven programs, though infrastructure gaps and cultural stigma hinder broader adoption. Strategic investments in mobile diagnostic units and AI-powered screening tools are critical to addressing unmet needs in these regions.

Key Regional Drivers5 items

North America: Advanced diagnostic ecosystems, high patient awareness, and reimbursement policies.

Europe: Stringent STI surveillance laws and integration of multiplex testing in sexual health clinics.

Asia Pacific: Government-funded STI control programs in India and China, coupled with rising urbanization.

Latin America: Cross-border collaborations for HIV/STI screening and mobile health (mHealth) adoption.

Middle East & Africa: Growing private-sector investments in diagnostic labs and NGO-led community outreach.

Competitive Landscape

The Diagnostic Testing of STDs competitive landscape is moderately consolidated, with a mix of global players and regionally focused firms. Major multinational corporations dominate through diversified product portfolios, regulatory approvals, and strategic partnerships, while smaller entities cater to niche markets or geographic areas with localized solutions. Pricing remains a critical lever, particularly in public healthcare systems, though differentiation is increasingly driven by technological advancements such as rapid molecular diagnostics and point-of-care testing. Certifications like CE marking and FDA clearance further shape competitive positioning, enabling firms to access high-growth markets.

Strategic priorities include R&D investment to address emerging pathogens, geographic expansion through acquisitions or joint ventures, and channel optimization to strengthen hospital and lab penetration. Competitive differentiation hinges on proprietary technologies (e.g., PCR-based assays), service models (e.g., diagnostic-as-a-service), and cost efficiencies from scalable manufacturing. A key challenge is rising compliance costs due to evolving regulatory standards, which disproportionately impact smaller firms. Simultaneously, commoditization pressures in basic serology tests are pushing players toward premium, multi-target assays to sustain margins.

Roche: Innovation pipeline focused on next-generation sequencing-based pathogen detection

Abbott: Regional expansion in Asia-Pacific via partnerships with public health organizations

Becton Dickinson: OEM tie-ups to integrate diagnostics into hospital automation systems

BioMerieux: Vertical integration to control raw material supply chains

Danaher: Premium pricing strategy for automated STI testing platforms

Hologic: Local manufacturing hubs to reduce distribution costs in emerging markets

Key Diagnostic Testing of STDs Companies6 items

Roche

Abbott

Becton Dickinson

BioMerieux

Danaher

Hologic

Market Ecosystem

The Diagnostic Testing of STDs ecosystem spans upstream suppliers of diagnostic components, midstream manufacturers and integrators, and downstream healthcare providers. Value is generated through the development of accurate testing technologies, streamlined production, and accessible diagnostic services, with control distributed across innovation, regulatory compliance, and clinical adoption.

Raw material suppliers — provide reagents, consumables, and substrates for diagnostic test kits

Diagnostic manufacturers — design and produce rapid tests, PCR-based assays, and immunoassay platforms

Technology providers — develop software for test automation, data analysis, and AI-driven diagnostics

System integrators — implement diagnostic workflows in laboratories and point-of-care settings

Distributors and channel partners — supply tests to public health agencies, hospitals, and private clinics

Healthcare end users — administer tests and interpret results in clinical laboratories and sexual health clinics

Regulatory bodies — oversee test validation, certification, and compliance with diagnostic standards

Control points reside with regulatory agencies dictating approval pathways and diagnostic manufacturers driving technological innovation. Dependency risks include raw material shortages and stringent validation protocols delaying market entry. Switching costs for laboratories adopting specialized testing platforms are high, while interoperability with electronic health records varies regionally, affecting adoption in decentralized healthcare systems.

Recent Industry Insights

The Diagnostic Testing of STDs industry trends have seen significant evolution over the past 18 months, driven by advances in technology and shifting healthcare priorities. Strategic partnerships have emerged, such as collaborations between diagnostic firms and telehealth platforms to streamline at-home testing and remote consultation services. Notable mergers & acquisitions include the acquisition of a rapid diagnostic startup by a global lab giant, enhancing its portfolio with a 15-minute multiplex STD test. Product/technology launches highlight innovations like AI-powered test readers and POCT (point-of-care testing) devices with 99% accuracy, addressing the need for speed and precision. Regulatory bodies, including the FDA, have expedited approvals for home-based kits, reflecting a shift in consumer trends toward privacy and convenience. Funding rounds surged, with a Series B round securing $50M for a company developing CRISPR-based STD diagnostics, while others expanded into emerging markets with high STI prevalence. Collectively, these developments underscore a forward-looking industry focused on accessibility, speed, and integration with digital health ecosystems.

Analyst Overview

The Diagnostic Testing of STDs market outlook remains robust, driven by rising global prevalence of sexually transmitted infections, increased awareness, and advancements in molecular diagnostics. Market attractiveness is high due to growing demand for rapid, accurate testing solutions and supportive public health initiatives. However, competitive intensity is escalating, with established players and emerging biotech firms vying for market share through innovation and strategic partnerships.

Key Insights4 items

Long-term outlook is optimistic, underpinned by aging populations, rising healthcare expenditure, and government funding for STD screening programs.

Innovation landscape is dynamic, with AI-driven diagnostics and point-of-care technologies gaining traction to address accessibility gaps.

Demand–supply balance faces pressure in low-income regions due to infrastructure limitations, creating opportunities for decentralized testing solutions.

Key risk factors include regulatory hurdles, reimbursement challenges, and potential sample contamination in rapid diagnostic tests.

Strategic investments in R&D and collaborations will be critical for stakeholders to navigate this landscape. The market’s growth trajectory hinges on overcoming supply-side constraints while leveraging technological breakthroughs to meet surging demand.

12 items

1. Executive Summary

2. Diagnostic Testing of STDs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Diagnostic Testing of STDs Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Diagnostic Testing of STDs Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Diagnostic Testing of STDs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Diagnostic Testing of STDs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Diagnostic Testing of STDs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Diagnostic Testing of STDs Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Diagnostic Testing of STDs Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Diagnostic Testing of STDs Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Diagnostic Testing of STDs Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Diagnostic Testing of STDs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Diagnostic Testing of STDs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Diagnostic Testing of STDs Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Diagnostic Testing of STDs Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Diagnostic Testing of STDs Market Competition by Key Manufacturers

9.1. Global Diagnostic Testing of STDs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Diagnostic Testing of STDs: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Roche

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Abbott

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Becton Dickinson

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. BioMerieux

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Danaher

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Hologic

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Diagnostic Testing of STDs Market

Figure 4: Global Diagnostic Testing of STDs Market: Drivers

Figure 5: Global Diagnostic Testing of STDs Market: Challenges

Figure 6: Global Diagnostic Testing of STDs Market: Trends

Figure 7: Global Diagnostic Testing of STDs Market: Opportunity

Figure 8: Global Diagnostic Testing of STDs Market: Restraint

Figure 9: Global Diagnostic Testing of STDs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Diagnostic Testing of STDs Market Value (USD Million) By Region

Figure 19: Global Diagnostic Testing of STDs Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Diagnostic Testing of STDs Market Value (USD Million) By Region

Figure 27: Global Diagnostic Testing of STDs Market Share (%) By: Regions (2032)

Figure 28: Global Diagnostic Testing of STDs Market Volume (K) By Region

Figure 29: Global Diagnostic Testing of STDs Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Diagnostic Testing of STDs Market Value (USD Million) By Region

Figure 37: Global Diagnostic Testing of STDs Market Share (%) By: Regions (2032)

Figure 38: Global Diagnostic Testing of STDs Market Volume (K) By Region

Figure 39: Global Diagnostic Testing of STDs Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Diagnostic Testing of STDs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Diagnostic Testing of STDs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Diagnostic Testing of STDs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Diagnostic Testing of STDs Market Value (USD Million) By Region

Table 14: Global Diagnostic Testing of STDs Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Diagnostic Testing of STDs Market Volume (K) By Region

Table 31: Global Diagnostic Testing of STDs Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Diagnostic Testing of STDs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Diagnostic Testing of STDs Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Diagnostic Testing of STDs Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Roche Basic Information And Sales Area

Table 52: Roche. Products Portfolio

Table 53: Abbott Basic Information And Sales Area

Table 54: Abbott. Products Portfolio

Table 55: Becton Dickinson Basic Information And Sales Area

Table 56: Becton Dickinson. Products Portfolio

Table 57: BioMerieux Basic Information And Sales Area

Table 58: BioMerieux. Products Portfolio

Table 59: Danaher Basic Information And Sales Area

Table 60: Danaher. Products Portfolio

Table 61: Hologic Basic Information And Sales Area

Table 62: Hologic. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Diagnostic Testing of STDs Market Value (USD Million) By Region

Table 72: Global Diagnostic Testing of STDs Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Diagnostic Testing of STDs Market Volume (K) By Region

Table 89: Global Diagnostic Testing of STDs Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Diagnostic Testing of STDs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Abbott; Becton Dickinson; BioMerieux; Danaher; Hologic
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options